– USA, MA – Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced the appointment of Paul J. Hastings as Chairman of its Board of Directors. Mr. Hastings has over three decades of operations experience in the biopharmaceutical industry, including roles as Chief Executive Officer at multiple public companies. Mr. Hastings is President and Chief Executive Officer of OncoMed Pharmaceuticals and Chairman of its Board since 2013.
“Paul has significant experience leading successful commercial organizations, and is the ideal person to join our Board at this transformational time for Proteon,” said Timothy Noyes, President and Chief Executive Officer. “Having served as Chief Executive Officer at multiple public companies, Paul brings deep operational and commercial expertise that will be of enormous value to Proteon as we prepare for the potential commercialization of vonapanitase.”
Mr. Hastings is the President and Chief Executive Officer of OncoMed Pharmaceuticals, and Chairman of the Board of Directors. Previously, Mr. Hastings served as President and Chief Executive Officer of QLT, Inc., and Axys Pharmaceuticals, which was acquired by Celera Corporation. Mr. Hastings also served as the President of Chiron BioPharmaceuticals, President and Chief Executive Officer of LXR Biotechnology, and held a series of management positions at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics. Mr. Hastings served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of Relypsa (sold to Galenica in 2016), ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals. He is currently on the boards of OncoMed Pharmaceuticals and Pacira Pharmaceuticals, serves as Vice Chairman of Biotechnology Innovation Organization (BIO), and is also on the board of directors of the California Life Sciences Association. Mr. Hastings received a B.S. in Pharmacy from the University of Rhode Island.
“I am thrilled to be joining the Proteon Board of Directors at this exciting time for the Company as it nears completion of its first Phase 3 clinical study of vonapanitase,” remarked Mr. Hastings. “I look forward to working with the Board and management team to help guide the development and execution of a successful strategy for the potential commercialization of vonapanitase.”
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials (PATENCY-1 and PATENCY-2) in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
For more information : http://www.proteontherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.